T1	Person 0 5	Women
T2	Condition 9 32	child-bearing potential
T3	Condition 42 71	biologically able to conceive
T4	Multiplier 87 90	two
T5	Device 100 130	highly effective contraception
T6	Condition 142 150	pregnant
T7	Negation 73 76	not
R1	Has_negation Arg1:T5 Arg2:T7	
R2	Has_multiplier Arg1:T5 Arg2:T4	
T8	Scope 0 71	Women of child-bearing potential, who are biologically able to conceive
A1	Optional T8
*	OR T5 T6
T9	Scope 73 150	not employing two forms of highly effective contraception or who are pregnant
R3	Has_scope Arg1:T8 Arg2:T9	
T10	Person 153 158	Women
T11	Condition 167 181	breast-feeding
T12	Person 191 196	males
T13	Condition 183 190	Fertile
T14	Observation 197 227	unwilling to use contraception
T15	Non-query-able 183 227	Fertile males unwilling to use contraception
T16	Post-eligibility 183 227	Fertile males unwilling to use contraception
T17	Condition 243 259	brain metastases
T18	Condition 278 294	brain metastases
T19	Observation 267 274	history
R4	Has_temporal Arg1:T18 Arg2:T19	
*	OR T18 T17
T20	Procedure 324 337	major surgery
T21	Procedure 345 359	intra-thoracic
T22	Procedure 345 350;361 371	intra -abdominal
T23	Procedure 345 350;376 383	intra -pelvic
*	OR T23 T22 T21
T24	Scope 345 383	intra-thoracic, -abdominal, or -pelvic
R5	Subsumes Arg1:T20 Arg2:T24	
T25	Subjective_judgement 324 337	major surgery
T26	Value 385 430	</= 4 weeks prior to starting study treatment
T27	Reference_point 406 430	starting study treatment
R6	Has_index Arg1:T26 Arg2:T27	
T28	Undefined_semantics 447 474	recovered from such therapy
T29	Subjective_judgement 447 474	recovered from such therapy
R7	Has_value Arg1:T20 Arg2:T26	
T30	Condition 503 521	pulmonary embolism
T31	Condition 536 556	deep vein thrombosis
T32	Qualifier 526 535	untreated
T33	Temporal 557 581	within the past 6 months
*	OR T31 T30
R8	Has_qualifier Arg1:T31 Arg2:T32	
T34	Observation 492 499	history
T35	Scope 503 556	pulmonary embolism, or untreated deep vein thrombosis
R9	Has_temporal Arg1:T35 Arg2:T34	
R10	Has_temporal Arg1:T35 Arg2:T33	
T36	Condition 583 627	Impairment of gastrointestinal (GI) function
T37	Condition 631 641	GI disease
T38	Qualifier 647 698	may significantly alter the absorption of dovitinib
T39	Undefined_semantics 647 698	may significantly alter the absorption of dovitinib
*	OR T37 T36
T40	Scope 583 641	Impairment of gastrointestinal (GI) function or GI disease
R11	Has_qualifier Arg1:T40 Arg2:T38	
T41	Condition 728 745	active malignancy
T42	Temporal 746 769	within the past 5 years
T43	Condition 781 804	cervical cancer in situ
T44	Negation 770 776	except
R13	Has_temporal Arg1:T41 Arg2:T42	
T45	Condition 806 838	in situ carcinoma of the bladder
T46	Condition 842 876	non-melanoma carcinoma of the skin
*	OR T45 T46 T43
T47	Scope 781 876	cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin
R12	Has_negation Arg1:T47 Arg2:T44	
R14	Has_scope Arg1:T41 Arg2:T47	
T48	Procedure 936 954	anticancer therapy
T49	Procedure 965 977	chemotherapy
T50	Procedure 979 992	immunotherapy
T51	Procedure 994 1010	hormonal therapy
T52	Drug 1015 1036	monoclonal antibodies
T53	Temporal 1037 1081	</= 2 weeks prior to starting the study drug
T54	Reference_point 1058 1081	starting the study drug
R15	Has_index Arg1:T53 Arg2:T54	
T55	Condition 1099 1146	recovered from the side effects of such therapy
T56	Negation 443 446	not
T57	Condition 447 474	recovered from such therapy
R16	Has_negation Arg1:T57 Arg2:T56	
*	OR T57 T20
*	OR T49 T50 T51 T52
T58	Scope 965 1036	chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies
R17	Subsumes Arg1:T48 Arg2:T58	
R18	Has_temporal Arg1:T48 Arg2:T53	
*	OR T48 T55
T59	Condition 1148 1157	Cirrhosis
T60	Condition 1159 1183	chronic active hepatitis
T61	Condition 1187 1215	chronic persistent hepatitis
*	OR T61 T60 T59
T62	Drug 1254 1263	prasugrel
T63	Drug 1286 1295	isoniazid
T64	Drug 1297 1306	labetolol
T65	Drug 1308 1321	trovafloxacin
T66	Drug 1323 1332	tolcapone
T67	Drug 1338 1347	felbamate
*	OR T63 T64 T65 T66 T67
T68	Negation 1265 1267	No
T69	Scope 1286 1347	isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate
R19	Has_negation Arg1:T69 Arg2:T68	
T70	Negation 1349 1351	No
T71	Drug 1370 1397	other investigational drugs
T72	Procedure 1401 1425	antineoplastic therapies
*	OR T72 T71
T73	Undefined_semantics 1370 1397	other investigational drugs
T74	Scope 1370 1425	other investigational drugs or antineoplastic therapies
R20	Has_negation Arg1:T74 Arg2:T70	
T75	Condition 1442 1467	impaired cardiac function
T76	Qualifier 1471 1493	clinically significant
T77	Condition 1494 1510	cardiac diseases
T78	Subjective_judgement 1471 1493	clinically significant
R21	Has_qualifier Arg1:T77 Arg2:T76	
*	OR T77 T75
T79	Undefined_semantics 1442 1467	impaired cardiac function
